DRUG · Unmapped registry intervention
Irbesartan/HCTZ
Find medicine records ·
Find other trials using this name
Clinical trial
Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension
NCT00095394
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Irbesartan monotherapy
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedIrbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Hypertensionunresolved
Interventions
Sponsors & collaborators
Bristol-Myers Squibblead sponsor
Sanoficollaborator
Mapped research locations
New YorkNew York, United States1ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1MiamiFlorida, United States1TorontoOntario, Canada1San AntonioTexas, United States1NashvilleTennessee, United States1BirminghamAlabama, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00095394 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.